|
Market Closed -
Nasdaq
01:00:00 13/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 10.08 USD | +5.66% |
|
+6.67% | -50.49% |
| 11-06 | Keros Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 | CI |
| 09-29 | Keros Therapeutics Expects $20 Million Milestone Payment From Takeda | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 198M | - | - | - | ||
| 68.45B | |||||
| 61.31B | |||||
| 55.73B | |||||
| 47.51B | |||||
| 44.68B |
Select your edition
All financial news and data tailored to specific country editions
